Personalized Management of Hyperglycemia in Type 2 Diabetes

Abstract

In June 2012, 13 thought leaders convened in a Diabetes Care Editors’ Expert Forum to discuss the concept of personalized medicine in the wake of a recently published American Diabetes Association/European Association for the Study of Diabetes position statement calling for a patient-centered approach to hyperglycemia management in type 2 diabetes. This article, an outgrowth of that forum, offers a clinical translation of the underlying issues that need to be considered for effectively personalizing diabetes care. The medical management of type 2 diabetes has become increasingly complex, and its complications remain a great burden to individual patients and the larger society. The burgeoning armamentarium of pharmacological agents for hyperglycemia management should aid clinicians in providing early treatment to delay or prevent these complications. However, trial evidence is limited for the optimal use of these agents, especially in dual or triple combinations. In the distant future, genotyping and testing for metabolomic markers may help us to better phenotype patients and predict their responses to antihyperglycemic drugs. For now, a personalized (“n of 1”) approach in which drugs are tested in a trial-and-error manner in each patient may be the most practical strategy for achieving therapeutic targets. Patient-centered care and standardized algorithmic management are conflicting approaches, but they can be made more compatible by recognizing instances in which personalized A1C targets are warranted and clinical circumstances that may call for comanagement by primary care and specialty clinicians.

Bone Marrow-Derived Mesenchymal Stem cells Infusion Ameliorates Hyperglycemia, Dyslipidemia, Liver and Kidney Functions in Diabetic Rats

“…Several other studies support the present finding that IR and Beta-cell dysfunction together underlie the development of diabetes [45], [46]. Glycated hemoglobin is produced by non-enzymatic condensation of glucose molecules with free amino acids on the globin component of hemoglobin.…”

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin

“…The number of antihyperglycemic agents has increased markedly, and the availability of multiple pharmacologic options is instrumental for treatment to target, which is a well-recognized strategy for the prevention of diabetes complications. Several guidelines recommend the use of dual or triple therapy based on glycated hemoglobin (HbA 1c ) levels, but clinical trial evidence defining the optimal use of available pharmacologic options, especially in dual or triple combinations, based on the degree of glycemic control is limited (3)(4)(5).…”

Treatment of Type 2 Diabetes: From “Guidelines” to “Position Statements” and Back

“…First, individualization of the stringency by which glycemic control targets are set (1,(16)(17)(18)(19) has left many open questions regarding the best glycemic target for a given patient (20)(21)(22). While the ADA/EASD Position Statement (1,2) supports a target HbA 1c of ,7% for most patients, it recommends a more stringent target (HbA 1c 6.0-6.5%) for select patients, as long as it can be achieved without increased risk of hypoglycemia or other prominent side effects.…”